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Abstract: Breast cancer remains a leading cause of disease and death among women throughout 
the world. Despite advances in drug therapy, development of novel and improved drugs for 
breast cancer continues to be of great interest. Lapatinib is a novel dual receptor tyrosine kinase 
inhibitor that is a selective and potent inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, both of 
which are growth promoting factors overexpressed in some breast cancers. Cell-based assays have 
proven lapatinib to be a potent inhibitor of ErbB-1 and ErbB-2 activation and breast cancer cell 
proliferation. In pharmacokinetic studies, lapatinib has shown mostly linear elimination kinetics 
over the daily dose range of 10–1600 mg and is metabolized by CYP3A4/5 and CYP2C19. Phase 
I, II, and III clinical trials involving lapatinib as monotherapy or in combination have shown 
promise for the treatment of advanced and metastatic breast cancer. Drug-drug interactions may 
occur secondary to concomitant administration of either CYP450 inhibitors or inducers. While 
lapatinib appear to be a promising addition to breast cancer therapy, several questions remain 
to be answered before its optimal role is elucidated.
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Introduction
Breast cancer is the most common cause of cancer among women with over 1 million 
new cases estimated to occur worldwide each year (Cox et al 2006). Despite advances 
in treatment, breast cancer remains a leading cause of death in developed countries. 
For example, breast cancer is the second leading cause of cancer-related deaths 
in several countries, including the United States (Jemal et al 2006). In the United 
Kingdom, breast cancer is the most common cause of death in women aged 40–50 
(McPherson et al 2000). Localized disease is associated with a substantially greater 
5-year survival rate (greater than 95%) than metastatic disease (less than 25%) (Cox 
et al 2006). While strides have been made in both detection and treatment of breast 
cancer, the need for new and improved breast cancer therapy, including chemothera-
peutic agents, clearly remains.
Pharmacologic therapy of breast cancer has been evolving and improving over the 
last half-century, and has increased in emphasis as the understanding of the natural 
history of breast cancer has shifted to being viewed as a disease that is systemic at the 
time of detection rather than localized and sometimes becoming systemic (Nabholtz 
and Gligorov 2005). In the 1970s, chemotherapy of breast cancer was character-
ized by non-anthracycline containing regimens, such as CMF (cyclophosphamide, 
methotrexate, 5-ﬂ  uorouracil), and were more successful in the adjuvant setting rather 
than treatment of metastatic disease. Breast cancer chemotherapy was improved in 
the 1980s with the introduction of the anthracyclines, and led to the development of 
multiple doxorubicin and epirubicin-containing regimens with superior reductions in 
breast cancer recurrence and mortality as compared with CMF (Levine and Whelan 
2006). Multiple novel chemotherapy agents were introduced in the 1990s for the Therapeutics and Clinical Risk Management 2007:3(4) 666
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treatment of breast cancer. Of these, the taxanes (paclitaxel, 
docetaxel) have emerged as particularly efﬁ  cacious either 
as monotherapy or in combination with anthracyclines for 
treatment of metastatic breast cancer (Nabholtz and Gligorov 
2005). The development and use of hormonal agents, such as 
tamoxifen, as adjuvant therapy has led to additional increases 
in the long-term survival rate for breast cancer (Early Breast 
Cancer Trialists’ Collaborative 2005).
A recent major advance in the pharmacotherapy of 
breast cancer is the introduction of drugs with especially 
high selectivity for tumor-specific targets. Trastuzumab, 
approved in the late 1990s, is a monoclonal antibody 
drug that is highly selective for targeting ErbB-2 (human 
epidermal growth factor receptor-2, HER-2), which is 
overexpressed in some breast cancers (Slamon et al 1987; 
Slamon and Godolphin 1989). In a 2001 study, Slamon 
and colleagues found that patients receiving trastuzumab 
plus either doxorubicin/cyclophosphamide or single-agent 
paclitaxel for metastatic breast cancer therapy was 
associated with improved time-to-progression relative to 
patients who did not receive trastuzumab (Slamon et al 
2001). Recently trastuzumab was shown to be of benefit 
when combined with paclitaxel after doxorubicin and 
cyclophosphamide in patients with surgically removed 
ErbB-2-positive breast cancer (Romond et al 2005).
Despite the aforementioned succession of improvements 
in breast cancer pharmacotherapy, the current extent of 
morbidity and mortality associated with the disease high-
lights the need for additional improvements in drug therapy. 
The development of targeted chemotherapy drugs holds 
the promise of retaining, and perhaps increasing, efﬁ  cacy 
while minimizing traditional chemotherapy-related toxicity 
(Pegram et al 2005; Flaherty and Brose 2006). One such 
promising drug is lapatinib, an orally available receptor tyro-
sine kinase inhibitor that, like trastuzumab, is highly selective 
for tumor-speciﬁ  c targets found in some breast cancers (Moy 
and Goss 2006; Nelson and Dolder 2006).
Pharmacology
Receptor tyrosine kinases are transmembrane-bound enzymes 
important to cell signaling pathways that control cell differ-
entiation and proliferation (Bennasroune et al 2004; Tibes et 
al 2005). Tyrosine kinases use adenosine triphosphate (ATP) 
to phosphorylate tyrosine residues on signaling proteins. 
Tyrosine kinase inhibitors are small molecule drugs that com-
petitively inhibit tyrosine kinase activity by binding to the 
ATP binding site of tyrosine kinases (Lin and Winer 2004). 
Evidence has implicated the human epidermal growth factor 
(HER) subfamily of receptor tyrosine kinases as important 
to the proliferation of some breast cancers; accordingly, the 
HER tyrosine kinases have become attractive targets for drug 
development (Slamon and Godolphin 1989; Hackel et al 
1999). There are 4 members in the HER subfamily of receptor 
tyrosine kinases: (1) ErbB-1 (epidermal growth factor 
receptor, EGFR, HER-1), (2) ErbB-2 (human epidermal 
growth factor receptor-2, HER-2, neu), (3) ErbB-3 (human 
epidermal growth factor receptor-3, HER-3) and (4) ErbB-4 
(human epidermal growth factor receptor-4, HER-4) (Hackel 
et al 1999; Lin and Winer 2004). Ligand binding to ErbB-1, 
ErbB-3 and ErbB-4 results in formation of homodimers and 
heterodimers among the 4 HER tyrosine kinases. ErbB-2 has 
no known ligands; however, it is the preferred heterodimer-
ization partner for ErbB-1, ErbB-3 and ErbB-4 (Graus-Porta 
et al 1997). Ligand binding and dimerization of HER kinases 
results in tyrosine kinase activity leading to activation of 
downstream signaling pathways and subsequent tumor cell 
proliferation (El-Rayes and LoRusso 2004).
Research suggests that several members of the HER 
subfamily of tyrosine kinases are important to breast can-
cer pathogenesis and are therefore attractive therapeutic 
targets. Overexpression of ErbB-2, which is present in 
approximately 20–25% of breast cancer, is associated with 
aggressive disease and shortened disease-free survival and 
overall survival (Slamon et al 1987; Slamon and Godolphin 
1989). ErbB-1 is of importance due to its association with 
ErbB-2, as evidence suggests that ErbB-1 and ErbB-2 work 
in synergy to produce an oncogenic effect (Graus-Porta 
et al 1997). Speciﬁ  cally, ErbB-2 dimerization with ErbB-1 
increases the afﬁ  nity for binding of epidermal growth factor 
(EGF) to ErbB-1 (Karunagaran et al 1996), and the binding 
of EGF to ErbB-1 subsequently increases the activation of 
ErbB-2 (King et al 1988). In addition to ErbB-2, ErbB-1 has 
also been found to be overexpressed in some breast cancers 
(Lin and Winer 2004).
Several types of clinically useful oncology drugs target the 
HER subfamily of tyrosine kinases including (1) monoclonal 
antibodies and (2) tyrosine kinase inhibitors. The mono-
clonal antibodies that target HER proteins are selective for 
a single target. For example, trastuzumab targets ErbB-2 
(Nahta and Esteva 2003) and cetuximab targets ErbB-1 
(Ng and Cunningham 2004). Most tyrosine kinase inhibi-
tors currently approved for cancer treatment target a single 
tyrosine kinase signaling pathway. For example, erlotinib 
and geﬁ  tinib selectively target ErbB-1 (Langer 2004). A 
salient feature of lapatinib is its ability to simultaneously 
inhibit the tyrosine kinase activity of 2 members of the Therapeutics and Clinical Risk Management 2007:3(4) 667
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HER subfamily of tyrosine kinases. Accordingly, lapatinib 
has been classiﬁ  ed as a dual tyrosine kinase inhibitor and 
described as having a broader spectrum of signal inhibition 
activity (Xia et al 2002; Flaherty and Brose 2006). Speciﬁ  -
cally, lapatinib is a selective and potent inhibitor of ErbB-1 
and ErbB-2 tyrosine kinases (Rusnak et al 2001a; Rusnak 
et al 2001b; Burris 2004).  The dual inhibition ErbB-1 and 
ErbB-2, tyrosine kinases that appear to work in synergy for 
promoting breast cancer proliferation, has been suggested as 
an explanation for the more potent inhibition of cancer cell 
growth than is seen when targeting either ErbB-1 or ErbB-2 
alone (Burris 2004).
Multiple in vitro studies have examined the activity of 
lapatinib for inhibition of ErbB-1 and ErbB-2 activity and 
inhibition of breast cancer cell proliferation in a variety of 
conditions. Lapatinib appears to be a potent inhibitor of 
ErbB-1 and ErbB-2, as evidenced by cell-free biochemical 
kinase activity assays in which the 50% inhibitory concen-
tration (IC50) of lapatinib for ErbB-1 and ErbB-2 was 10.8 
and 9.2 nM, respectively (Rusnak et al 2001b). In cell-based 
assays the potency of lapatinib for inhibition of ErbB-2-
overexpressing breast cancer cell growth varies depending 
on the cell line. For example, lapatinib is a relatively potent 
inhibitor of BT474 breast cancer cell growth (IC50 100 nM) 
but is 30- to 40-fold less potent against MCF-7 and T47D 
breast cancer cells (Rusnak et al 2001b). Additional cell-
based studies have shown that lapatinib inhibits ErbB-1 and 
ErbB-2 activation and cell proliferation in breast cancer cell 
lines that overexpress either ErbB-1 or ErbB-2 (Xia et al 
2004; Zhou et al 2004; Spector et al 2005). Several cell-
based studies have demonstrated that lapatinib combined 
with trastuzumab enhances breast cancer cell apoptosis in 
ErbB-2-overexpressing breast cancer cells and breast cancer 
cells resistant to trastuzumab monotherapy (Xia et al 2005; 
Konecny et al 2006). Finally, recent evidence suggests that 
lapatinib, unlike trastuzumab and geﬁ  tinib, induces down-
regulation of the apoptosis inhibitor survivin, which in turn 
leads to apoptosis of breast cancer cells (Xia et al 2006).
Pharmacokinetics
Lapatinib is administered as an oral drug formulated as the 
monohydrated ditosylate derivative. In initial pharmacoki-
netic and safety studies, the daily dosage range of lapatinib 
was 10–1600 mg (Bence et al 2005; Burris et al 2005). Larger 
phase II and phase III trials have typically used a dosing 
range of 750–1500 mg (Table 2). Lapatinib has generally 
displayed linear elimination pharmacokinetics over a wide 
daily dosage range (10–1600 mg/day).
At the time of writing, oral bioavailability data had not 
been published for lapatinib; however, one study suggests 
that the oral absorption of lapatinib is partially limited by 
low solubility and that recent food intake may contribute to 
variability in absorption (Burris et al 2005). Following an 
oral dose, onset of absorption is delayed about 30 minutes 
and peak serum concentrations (Cmax) occur after 3–4 hours 
(Bence et al 2005). In the dosage range of 10 to 250 mg, the 
peak serum concentrations of lapatinib increased in a dose-
proportional manner.
With chronic oral therapy lapatinib accumulates in the 
body (Bence et al 2005). Accordingly, single-dose phar-
macokinetic studies do not reﬂ  ect the area under the curve 
(AUC) and elimination half-life of lapatinib that would result 
from a chronic oral administration dosing regimen used 
for breast cancer therapy. At doses over 100 mg per day, 
lapatinib trough levels increase by approximately 50% over 
6 to 8 days of therapy. This ﬁ  nding has led investigators to 
conclude that lapatinib has an effective elimination half-life 
of approximately 24 hours with chronic dosing, as opposed to 
the measured elimination half-life of 6 to 11 hours observed 
with single-dose studies, suggesting that the preferred dosing 
interval is once daily (Bence et al 2005).
Lapatinib undergoes both hepatic and intestinal 
metabolism by cytochrome P450 isoenzymes (CYP450). 
In vitro studies indicate that lapatinib undergoes oxidative 
metabolism predominantly by the CYP3A4/5 isoforms and 
to a lesser degree by the CYP2C19 isoform (Herendeen 
et al 2004; Smith et al 2004). Neither the percent of the dose 
that is eliminated by metabolism nor the major route(s) of 
elimination for lapatinib have been published at the time of 
writing.
Efﬁ  cacy
Lapatinib’s efficacy in breast cancer has been examined 
in several trials and is summarized in Table 2. Most of 
these investigations were ongoing open-label, Phase I 
Table 1  Lapatinib in brief
Mechanism of action  Receptor tyrosine kinase inhibitor at
  ErbB-1 and ErbB-2
Route of administration  Oral as lapatinib ditosylate 
Daily dose range  750–1500 mg given once or twice daily
Metabolism  CYP3A4/5 and CYP2C19
Common adverse effects  Rash, diarrhea, nausea, fatigue, anorexia
Drug-drug interactions  CYP450 inhibitors may increase AUC of
 lapatinib
  CYP450 inducers may decrease AUC of
 lapatinibTherapeutics and Clinical Risk Management 2007:3(4) 668
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and II trials with small numbers of patients. Nonetheless, 
these studies demonstrate substantial promise for lapa-
tinib. Results of three Phase I or II studies (Blackwell et 
al 2005; Gomez et al 2005; Storniolo et al 2005) have 
been published involving lapatinib’s use in advanced 
or metastatic breast cancer. These studies involved 121 
patients receiving oral doses of lapatinib between 750 
and 1500 mg per day. Response rates in these three trials 
ranged from 9% to 39% and stabilization of disease for 
patients treated with lapatinib were noted to be between 
15% and 46% among the three trials. The response rates 
reported in these trials are relatively low; however, find-
ings from these studies must be examined in the context 
of metastatic, refractory and/or relapsed breast cancer 
(ie, generally low response rate and poor prognosis). The 
ability of lapatinib to effect positive results in a subset 
of patients with traditionally difficult to treat cancer is 
also highlighted by results from Spector and colleagues 
(Spector et al 2006) in a trial involving inflammatory 
breast cancer. Inflammatory breast cancer is relatively 
uncommon but is aggressive and possesses a poor progno-
sis (Ueno et al 1997; Peck 2006). In this study involving 
17 individuals with relapsed or refractory inflammatory 
breast cancer, a complete or partial response rate of 47% 
was reported. This number rose to 82% when examining 
just the cohort that overexpressed ErbB2.
The most encouraging results involving lapatinib are from 
a Phase III trial involving more than 300 patients with refrac-
tory advanced metastatic breast cancer randomized to either 
lapatinib and capecitabine or capecitabine monotherapy. 
Patients in the combination group received 1250 mg daily 
of lapatinib and 2000 mg/m2 of capecitabine on days 1–14. 
Patients enrolled into the capecitabine monotherapy group 
received 2500 mg/m2 also administered on days 1–14. Both 
treatment arms received medications in three week cycles. 
Ninety-six percent of patients had stage IV breast cancer and 
80% of patients had at least two metastatic sites. Ninety-eight 
percent of patients had previously received anthracyclines, 
taxanes, and trastuzumab. Thus, these patients had signiﬁ  cant 
disease that had progressed or relapsed despite a variety 
of standard chemotherapy agents. The investigators noted 
substantial beneﬁ  ts favoring patients receiving the combina-
tion of lapatinib and capecitabine compared to capecitabine 
alone, including median time to progression (36.9 weeks 
vs. 19. 7 weeks, p < 0.001), patients who progressed or 
died (28% vs. 43%, p < 0.001) and overall survival (22.5% 
vs. 14.3%, p = 0.113) (Geyer et al 2006). Beneﬁ  cial results 
of the study led to the trial’s independent data monitoring 
committee recommending premature study discontinuation 
(GlaxoSmithKline 2006).
A substantial proportion of women with metastatic 
breast cancer will experience central nervous system (CNS) 
disease. Lin and colleagues (Lin et al 2006) examined the 
efﬁ  cacy and safety of lapatinib in 39 such patients. The 
mean age of patients was 52 years and 44 percent of these 
women were ErbB-2 positive. All patients had developed 
CNS lesions while on trastuzumab and most had progressed 
despite radiation. In addition, 90% of patients had received 
previous taxanes and 67% had received anthracyclines. 
Eligible individuals received 750 mg of lapatinib twice 
daily in an open-label fashion for 8 weeks. Imaging was 
performed at baseline, week 1, and week 8 to determine the 
objective response rate in the brain. In terms of efﬁ  cacy, 
two patients achieved a partial response rate based on 
Response Evaluation Criteria In Solid Tumors (RECIST) 
and ﬁ  ve additional subjects were found to have experienced 
at least a 30% volumetric reduction in their CNS lesions. 
The median time to treatment failure was approximately 
3 months. In terms of safety data, the most common grade 
3 toxicities were diarrhea (21%), fatigue (16%), and rash 
(5%). No patients developed grade 4 toxicities. Further-
more, no grade 3 or 4 declines in left ventricular ejection 
fraction were noted; however, 4 cases of asymptomatic 
reductions in ejection fraction were reported (Lin et al 
2006; Peck 2006). The study by Lin and colleagues found 
only low objective response rates of lapatinib as adjuvant 
therapy in patients with metastatic cancer involving the 
brain. Nonetheless, some activity was demonstrated. Such 
a ﬁ  nding may prove to be important when considering the 
poor prognosis of patients with metastases to the brain 
(Engel et al 2003).
Although not all predictors of lapatinib response are 
currently understood, selecting patients who are more likely 
to respond to the dual tyrosine kinase inhibitor appears 
important. For example, in an analysis of the biological 
effect of lapatinib on tumor tissue (Burris et al 2005), 
investigators reported that patients with breast cancer who 
had higher pretreatment expression of ErbB-2 and activated 
ErbB-2 (p-ErbB2) were more likely to achieve a complete 
or partial response. This ﬁ  nding is supported by Spector and 
colleagues’ (Spector et al 2006) examination of lapatinib 
monotherapy in relapsed or refractory inﬂ  ammatory breast 
cancer. In this study, 11 patients were overexpressors of 
ErbB-2 and six were not. Eight of the 11 overexpressors 
achieved at least a partial response, while none of the ErbB-2 
non-overexpressors responded to lapatinib.Therapeutics and Clinical Risk Management 2007:3(4) 670
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Although most published trials of lapatinib involve its 
use in breast cancer, results of several investigations have 
been published regarding other solid tumors. Relatively lim-
ited activity has been reported with lapatinib as second-line 
therapy in metastatic colorectal cancer (Fields et al 2005) 
and in bladder cancer (Wulﬁ  ng et al 2005). Ongoing trials 
are also examining lapatinib’s efﬁ  cacy in lung and renal cell 
cancer (Johnston and Leary 2006).
Ongoing breast cancer trials ( Johnston 
and Leary 2006)
There are a number of ongoing phase II and III trials with lap-
atinib in breast cancer. These investigations involve lapatinib 
in both treatment refractory patients and in patients where 
lapatinib represents ﬁ  rst-line therapy. Once completed, these 
studies should provide valuable information regarding the 
best uses of lapatinib in breast cancer. The primary endpoints 
of these investigations are generally time to disease progres-
sion for the phase III trials and objective response rate for 
the phase II trials. Subjects per study range from 60 to 1200. 
In patients with ErbB-2-positive refractory breast cancer, 
lapatinib is being examined in an open-label fashion as 
monotherapy (EGF105084, EGF103009) and in randomized 
controlled trials with and without trastuzumab (EGF104900) 
or fulvestrant (CALGB 40302). Ongoing investigations of 
lapatinib as ﬁ  rst-line therapy involve various combinations 
of lapatinib with taxanes utilizing a number of study designs. 
Three phase III, randomized, double-blind, controlled trials 
(EGF104383, EGF104535, and EGF3001) involve patients 
with no previous treatment for metastatic breast cancer being 
randomized to active treatments of paclitaxel and lapatinib 
with or without trastuzumab. These trials will help to pro-
vide information on whether the addition of lapatinib will 
increase the efﬁ  cacy of current taxane/trastuzumab-based 
regimens. An additional phase III, randomized, double-
blind, placebo-controlled trial (EGF 30008) is examining 
the effects of letrozole with or without lapatinib in post-
menopausal women with metastatic breast cancer. This 
particular investigation is treating patients without regard 
to ErbB-2 status. Such a study has the potential to provide 
valuable data regarding the place of lapatinib in treatment 
sequences involving hormonal therapies such as tamoxifen 
(Johnston and Leary 2006).
Adverse effects
Safety data derived from phase I, II, and III trials involving 
lapatinib have demonstrated the medication’s relatively toler-
able side effect proﬁ  le. In the largest phase III study published 
to date (Geyer et al 2006), the prevalence of side effects 
leading to discontinuation were similar between patients 
receiving lapatinib and capecitabine (14%) and those pa-
tients receiving only capecitabine (11%) (GlaxoSmithKline 
2006). The most common side effects reported in patients 
receiving both lapatinib and capecitabine were diarrhea, 
hand-foot syndrome, and rash. The vast majority of these 
toxicities were grade 3 or less. Grade 3 diarrhea was reported 
in 12% of the lapatinib and capecitabine group and 11% of 
the capecitabine monotherapy group. Grade 3 palmar-plantar 
erythema occurred in 6% of lapatinib and capecitabine-
treated patients and 5% of the capecitabine-treated patients. 
Rash was found in 3% of the lapatinib group and 7% in the 
capecitabine monotherapy group. Four patients in the lapa-
tinib group were noted to have experienced a cardiac side 
effect (ie, reduction in left ventricular ejection fraction), all 
of which were asymptomatic (Peck 2006).
The adverse effect proﬁ  le of lapatinib, when derived from 
phase I and II trials, is similar to that of the above-mentioned 
phase III trial. For instance, in a phase I trial involving a 
variety of carcinomas (Burris et al 2005), the most common 
side effects associated with doses of lapatinib ranging from 
500–1600 mg per day were diarrhea (42%), rash (31%), 
nausea (13%), and fatigue (10%). Ninety six percent of these 
reported adverse effects were deemed mild or moderate. In 
another Phase I investigation involving doses of lapatinib up 
to 1800 mg daily, the most frequently reported side effects 
were also rash, diarrhea, nausea, fatigue, and anorexia. All of 
these were considered mild to moderate in severity (Versola 
et al 2004). Very similar side effects have been reported in 
Phase II trials. Overall, grade 4 (life-threatening or disabling 
adverse event) or 5 (death related to adverse event) have been 
rarely reported in clinical trials involving lapatinib.
Reports of decreased cardiac function have surfaced from 
individual trials of lapatinib. Perez and colleagues (Perez 
et al 2006) pooled safety data from 2,812 subjects who 
had received lapatinib in clinical trials. Cardiac risk factors 
including age, presence of existing cardiovascular disease, 
exposure to mediastinal radiation therapy, and treatment 
with chemotherapeutic agents with known cardiac effects 
were collected. The primary safety outcome was a signiﬁ  cant 
change in left ventricular ejection fraction (LVEF) (grade 3 
toxicity or at least a 20 percent decline in LVEF). Only 37 
of the 2,812 patients (1.3%) who had received lapatinib were 
reported to have experienced decreased LVEF. The median 
age of these 37 individuals was 59 years and 68 percent 
were female. Twenty-two of the patients were receiving 
lapatinib monotherapy and 15 were receiving additional Therapeutics and Clinical Risk Management 2007:3(4) 671
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chemotherapeutic agents. In the majority of cases, decreased 
LVEF was noted within nine weeks of lapatinib initiation. 
The majority of patients were asymptomatic and most symp-
tomatic patients responded to standard heart failure treat-
ments in a timely manner. Thirty-four of the 37 individuals 
who experienced declines in LVEF had confounding factors 
that may have contributed to their reduced LVEF, making 
the determination of a clear relationship between lapatinib 
use and depressed cardiac function difﬁ  cult. Nonetheless, the 
decrease in LVEF that was experienced by these persons was 
noted to have resolved or improved in 57% of cases, 50% 
of which occurred with continued lapatinib treatment. Thus, 
results from Perez and colleagues support the notion that 
lapatinib-associated declines in LVEF, although potentially 
serious, are uncommon, usually asymptomatic, and generally 
reversible (Peck 2006; Ruiz-Palacios et al 2006).
Drug interactions
At this time there is little published data regarding the drug-
drug interaction potential of lapatinib. In general, lapatinib 
appears to have little potential to alter the pharmacodynamic 
effects of other medications. Evidence from a phase I phar-
macokinetic study in which lapatinib and paclitaxel were 
administered either alone or in combination to 18 cancer 
patients suggested that treatment-related toxicities such as 
neuropathy, diarrhea, rash and myalgias occurred in greater 
intensity with the combination therapy (Jones et al 2004).
Given the fact that lapatinib is metabolized by CYP3A4, 
CYP3A5 and CYP2C19, a likely source of drug-drug 
interactions would be concomitant use with other drugs that 
inhibit or induce the activity of these CYP450 isoforms. Of 
the CYP450 isoenzymes, CYP3A4 is especially important 
in terms of drug-drug interactions due to the fact that it is the 
most plentiful CYP450 in the liver and accounts for more 
drug metabolism than any other CYP450 (Wilkinson 2005; 
Zhou et al 2005).
The effect of CYP3A4 inhibition on the pharmacokinet-
ics of a single 100 mg dose of lapatinib was studied in an 
open-label, randomized, two-way crossover study of 22 
healthy adults using 200 mg twice daily of ketoconazole, a 
potent inhibitor of CYP3A4 (Smith et al 2004). In this study 
ketoconazole administration resulted in a 3.6-fold increase 
in lapatinib AUC and an approximately 2-fold increase in 
maximum blood concentration (Cmax) and elimination half-
life, suggesting that concomitant use of CYP3A4 inhibitors 
with lapatinib may cause clinically important drug-drug 
interactions. In a study with similar methodology, the effect 
of carbamazepine, a known inducer of CYP450 metabolism, 
on the pharmacokinetics of a single lapatinib dose was stud-
ied (Herendeen et al 2004). Results from this study showed 
that carbamazepine administration resulted in 72% and 58% 
decreases in lapatinib AUC and Cmax, respectively. Interest-
ingly, the elimination half-life of lapatinib was unchanged 
in this study. Both of these studies only examined the effect 
of CYP450 inhibition and induction on pharmacokinetic 
parameters for a single dose of lapatinib. Certain pharmaco-
kinetic parameters, such as the elimination half-life, change 
as lapatinib accumulates in the body with multiple-dosing 
(Bence et al 2005), and results of studies utilizing only a 
single dose of lapatinib may not accurately extrapolate to 
the expected lapatinib clinical scenario in which patients 
receive chronic therapy. Regardless, both studies highlight 
the fact that clinicians should be vigilant for potential drug-
drug interactions if lapatinib is used with other medications 
that either induce or inhibit CYP450 activity.
Lapatinib’s future
Lapatinib is an oral dual receptor tyrosine kinase inhibitor 
that offers a wider spectrum of signal transduction inhibition 
and has demonstrated substantial promise for breast cancer 
treatment in Phase I, II, and III trials. A number of unresolved 
issues regarding lapatinib exist, some of which will hopefully 
begin to be resolved with results of pending investigations. 
One of the therapeutic challenges associated with the use of 
lapatinib is its role in breast cancer treatment. Speciﬁ  cally, 
should this medication be used in conjunction with or in 
place of trastuzumab? In what sequence with such agents as 
tamoxifen and anastrazole will lapatinib produce the most 
efﬁ  cacy? Does lapatinib have a role as ﬁ  rst-line therapy in 
breast cancer as monotherapy or in conjunction with other 
chemotherapeutic agents? If lapatinib is proven to improve 
survival in the adjuvant setting in future trials, then how long 
do patients need to continue therapy? Another challenge 
is to determine how a patient’s ErbB-1 and ErbB-2 status 
affects response rates and safety of lapatinib. Additional 
data regarding pharmacokinetics and the drug-drug interac-
tion potential in the target population of lapatinib will be 
necessary to ensure optimal and safe use of lapatinib. Yet 
another area of need is to determine lapatinib’s role in other 
types of cancer.
Lapatinib is representative of emerging novel anticancer 
drugs that are targeted to tumor-speciﬁ  c markers and offer the 
promise of improved efﬁ  cacy and decreased toxicity relative 
to traditional cancer chemotherapeutics. The potential for 
lapatinib to improve some aspects of breast cancer therapy 
appears to be substantial. However, multiple questions Therapeutics and Clinical Risk Management 2007:3(4) 672
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remain to be answered before the optimal clinical role of 
lapatinib emerges.
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